Oculis Holding AG
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
OCS | IC
Overview
Corporate Details
- ISIN(s):
- CH1242303498 (+1 more)
- LEI:
- 5067005370C2KK324336
- Country:
- Switzerland
- Address:
- Bahnhofstrasse 7, 6300 Zug
- Website:
- https://www.oculis.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Oculis Holding AG is a global, clinical-stage biopharmaceutical company dedicated to developing innovative therapies to save sight and improve eye care. The company focuses on ophthalmology, addressing diseases with high unmet medical needs through a pipeline of novel treatment candidates. Its key assets include OCS-01, a topical eye drop using its proprietary OPTIREACH® technology for Diabetic Macular Edema (DME); Licaminlimab (OCS-02), an anti-TNFα eye drop for Dry Eye Disease (DED); and Privosegtor (OCS-05), a neuroprotective therapy for Acute Optic Neuritis. Oculis aims to transform treatment paradigms by developing potentially first-in-class, non-invasive therapies for major ocular diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-14 22:05 |
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 1.2 KB | ||
| 2025-10-14 10:00 |
Regulatory News Service
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO …
|
English | 15.5 KB | ||
| 2025-10-08 22:05 |
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 949 bytes | ||
| 2025-10-06 10:07 |
Regulatory News Service
Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugab…
|
Icelandic | 18.7 KB | ||
| 2025-10-06 10:07 |
Regulatory News Service
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neurit…
|
English | 16.8 KB | ||
| 2025-09-26 22:05 |
Director's Dealing
Oculis Publishes Notification of Transactions by Person Discharging Managerial …
|
English | 1.0 KB | ||
| 2025-09-22 10:00 |
Regulatory News Service
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor …
|
English | 11.4 KB | ||
| 2025-09-09 22:05 |
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 952 bytes | ||
| 2025-09-04 19:00 |
Regulatory News Service
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
|
English | 6.5 KB | ||
| 2025-09-03 22:05 |
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 950 bytes | ||
| 2025-09-01 10:00 |
Regulatory News Service
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Op…
|
English | 17.7 KB | ||
| 2025-08-28 10:00 |
Regulatory News Service
Oculis to Participate in Upcoming September Investor Conferences
|
English | 6.1 KB | ||
| 2025-08-25 10:00 |
Board/Management Information
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-R…
|
English | 13.2 KB | ||
| 2025-08-21 22:05 |
Earnings Release
Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri f…
|
Icelandic | 20.6 KB | ||
| 2025-08-21 22:05 |
Earnings Release
Oculis Reports Q2 2025 Financial Results and Provides Company Update
|
English | 18.3 KB |
Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oculis Holding AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oculis Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
